Summary
A critical component in controlling the production of biological products derived from human and animal cell lines in the characterization and testing of banked cell substrates. The objective is to confirm the identity, purity, and suitability of these cells for manufacturing use. Quality concerns for biological products derived from cell lines originate from the presence of cellular and adventitious contaminants. Well-characterized cell banks not only permit a consistent source of production cells throughout the life of a product but also decrease the likelihood of contamination by other cell lines and adventitious agents. An important part of qualifying a cell line is choosing the appropriate testing for the presence of adventitious contaminants. The qualification of cell banks includes tests for cell identity and endogenous and adventitious microbial contaminants (bacteria, fungi, mycoplasmas, and viruses). For cells producing recombinant deoxyribonucleic acid-derived products, analysis of the expression construct at the nucleic acid level (genetic stability) is also a primary concern. The strategy for designing a safety-testing program for banked cells should be based on sound scientific principles and current regulatory guidance.
Article PDF
Similar content being viewed by others
References
Beale, A. J. Choice of cell substrate for biological products. Adv. Exp. Med. Biol. 118:83–97; 1979.
Berthold, W.; Werz, W.; Walter, J. K. Relationship between nature and source of risk and process validation. In: Brown, F.; Lubiniecki, A. S., ed. Viral safety and evaluation of viral clearance from biopharmaceutical products. Dev. Biol. Stand., vol. 88. Basel, Switzerland: Karger, 1995: 59–71.
Chen, T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell Res. 104:255–262; 1977.
Code of Federal Regulation. Title 9, Parts 113.46, 113.47, 113.51. Subchapter E—viruses, serums, toxins and analogous products; organisms and vectors. Washington, DC: U.S. Government Printing Office; 2004.
Code of Federal Regulations Title 21, Part 210. Current good manufacturing practice in manufacturing, processing, packing, and holding of drugs, general. Washington, DC: US Government Printing Office; 2004.
Committee for Proprietary Medicinal Products, Ad Hoc Working Party on Biotechnology/Pharmacy, European Commission. Production and Quality Control of Monoclonal Antibodies (revision). Note for Guidance, III/5271/94, 1995.
European Medicines Evaluation Agency [EMEA]. Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products, CPMP/BWP/1793/02.
European Pharmacopoeia, Section 2.6.7, 2003.
Freshney, R. I., ed. Culture of animal cells: a manual of basic technique. 4th ed. New York: Wiley-Liss; 2000.
Hayflick, L. A brief history of cell substrates used for the preparation of human biologicals. In: Brown, F.; Lewis, A., Jr.; Peden, K.; Krause, P., ed. Evolving scientific and regulatory perspectives on cell substrates for vaccine development. Dev. Biol. Stand., vol. 106. Basel, Switzerland: Karger, 1999:5–24.
Hopps, H. E.; Petricciani, J. C., eds. Abnormal cells, new products and risks, Gaithersburg, MD: Tissue Culture Association; 1985.
Horaud, F. Viral safety of biological products and the concept of validation. In: Brown, F.; Lubiniecki, A. S., ed. Viral safety and evaluation of viral clearance from biopharmaceutical products. Dev. Biol. Stand., vol. 88. Basel, Switzerland: Karger; 1995;19–24.
ICH Q5A Guidance for Industry: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human and Animal Origin. FDA implementation: published in the federal register, vol. 63, no. 185, September 24, 1998, 51074–51084.
ICH Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products. FDA implementation: published in the federal register, vol. 61, no. 37, February 23 1996, 7006–7008.
ICH Q5D Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products. FDA implementation: published in the federal register, vol. 63, no. 182, September 21, 1998, 50244–50249.
National Cancer Institute Monograph (USA), 29. 1968.
Olson, L. D.; Barile, M. F. Mycoplasma infection of cell cultures; isolation and detection. J. Tissue Cult. Methods 11:175–179; 1988.
Petricciani, J. C. Cell line issues: historical and future perspectives. In: Brown, F.; Esber, E. E.; Williams, M., ed. Continuous cell lines—an international workshop on current issues. Dev. Biol. Stand., vol. 76. Basel, Switzerland: Karger, 1991:5–11.
Petricciani, J. C.; Hopps, H. E.; Chapple, P. J., eds. Cell substrates. New York: Plenum; 1979.
Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. CBER/FDA; 1993.
Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. CBER/FDA; 1997.
Symposium on Diploid Cells, Minimum requirements of the establishment of a HDCS to be used for the production of human virus vaccines and minimum requirements for the production of human virus vaccines in HDCS. In: Proceedings of the symposium on the characterization and uses of human diploid cell strains. Opatija, Yugoslavia: Permanent Section of Microbiological Standardization; 1963; p. 709–715.
WHO, Requirements for continuous cell lines used for biological production, In: WHO Expert Committee on biological standardization. Geneva, Switzerland: World Health Organization, 1987, Annex 3 (WHO Technical Report Series No. 745).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schiff, L.J. Review: Production, characterization, and testing of banked mammalian cell substrates used to produce biological products. In Vitro Cell.Dev.Biol.-Animal 41, 65–70 (2005). https://doi.org/10.1290/0503024.1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1290/0503024.1